Runben Biotechnology (SH:603193) NORTHEAST SECURITIES·2025-10-23 08:12Investment Rating - The report maintains a "Buy" rating for the company [4][7]. Core Views - The company reported a revenue of 1.238 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 19.28%. The net profit attributable to the parent company was 266 million yuan, up 1.98% year-on-year [1]. - The company is expected to benefit from increased marketing investments in preparation for the Q4 peak season, particularly in the children's care segment [2][3]. - The company has a robust product system and refined operational capabilities, which are expected to enhance its market share as it continues to expand its product and channel offerings [4]. Financial Performance Summary - For Q3 2025, the company achieved a revenue of 342 million yuan, a 16.67% increase year-on-year. The net profit attributable to the parent company was 78 million yuan, down 2.89% year-on-year [1][2]. - The revenue breakdown for Q3 2025 shows that mosquito repellent products generated 132 million yuan (+48.54%), while children's care products brought in 146 million yuan (-2.76%) [2]. - The overall expense ratio for the first three quarters of 2025 was 33.41%, an increase of 4.67 percentage points year-on-year, primarily due to increased marketing expenditures [3]. - The gross margin for the first three quarters of 2025 was 58.27%, a slight decrease of 0.06 percentage points year-on-year, while the net profit margin was 21.50%, down 3.65 percentage points [3]. Future Projections - The company expects revenues of 1.598 billion yuan, 1.939 billion yuan, and 2.359 billion yuan for 2025, 2026, and 2027, respectively. The net profit attributable to the parent company is projected to be 318 million yuan, 392 million yuan, and 483 million yuan for the same years [4][6].